What Happens If The Confirmatory Clinical Trial For Biogen’s Alzheimer’s Drug Fails? In one of its most anticipated decisions of 2021, the FDA surprisingly granted marketing clearance to Biogen’s new drug for Alzheimer’s disease (AD), Aduhelm (generic name: aducanumab).